Protalix BioTherapeutics (PLX) Depreciation & Amortization - Total (2024 - 2026)

Protalix BioTherapeutics has reported Depreciation & Amortization - Total for 3 years, with the latest figure at $132000.0 in Q2 2026.

• On a quarterly basis, Depreciation & Amortization - Total rose 12.82% year-over-year to $132000.0 in Q2 2026; TTM through Jun 2026 was $1.3 million, a 15.01% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 12.35% from the prior year.
• Depreciation & Amortization - Total was $132000.0 for Q2 2026 at Protalix BioTherapeutics, down from $404000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization - Total was $404000.0 in Q1 2026, with the low at $117000.0 in Q2 2025.
• Average Depreciation & Amortization - Total over 3 years is $304444.4, with a median of $334000.0 recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization - Total tumbled 63.32% in 2025, then increased 16.76% in 2026.
• Over 3 years, Depreciation & Amortization - Total stood at $334000.0 in 2024, then climbed by 15.87% to $387000.0 in 2025, then sank by 65.89% to $132000.0 in 2026.
• The last three Depreciation & Amortization - Total figures came in at $132000.0 (Q2 2026), $404000.0 (Q1 2026), and $387000.0 (Q4 2025), per Business Quant data.